Tenderwize
Retour à la recherche

Open-house rebate agreement for Glatirameracetat injection solution in a prefilled syringe

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Dec 03, 2027 · 461 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Glatirameracetat in der Darreichungsform Injektionslösung in einer Fertigspritze, ATC L03AX13

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The buyer explicitly states this is an open-house model and not a normal open procedure; procurement-law remedies and c...

Contract documents must be submitted via the communication area, not the offer area; paper originals must be in duplica...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive open-house rebate agreements for Glatirameracetat in the form of injection solution in a prefilled syringe, ATC L03AX13.
  • Supply of pharmaceutical products under identical, pre-set contract terms.
Afficher le résumé complet

This is an open-house pharmaceutical rebate agreement for Glatirameracetat injection solution in a prefilled syringe (ATC L03AX13) offered by AOK Bayern. It is not a competitive award procedure in the usual sense: the buyer states that all interested pharmaceutical companies meeting the stated suitability requirement may join on identical, non-negotiable terms. The contract period runs from 01.02.2026 to 31.01.2028, with accession possible until 03.12.2027. Submission is either by handwritten originals in duplicate or electronically with a qualified electronic signature via DTVP. No contract value is provided.

Risques

The buyer explicitly states this is an open-house model and not a normal open procedure; procurement-law remedies and c...

Contract documents must be submitted via the communication area, not the offer area; paper originals must be in duplica...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The contract must be completed and signed, together with the annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Glatirameracetat injection solution in a prefilled syringe

Single lot covering non-exclusive open-house rebate agreements for the medicinal product Glatirameracetat in injection solution in a prefilled syringe, ATC L03AX13. The lot is for supplies and appears to be a framework/open-house arrangement with no negotiated individual terms. The lot information comes from structured data and notice text.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Jan 2026 - Jan 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Dec 03, 2027

Détails de la procédure

Date de publication
14 Dec 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
830560-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30